Table 6 Logistic regression analysis for clinical response
Univariable analysis | Multivariable analysis* | |||
|---|---|---|---|---|
Factors | Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value |
Male (ref. female) | 0.408 (0.086–1.938) | 0.260 | ||
Age (ref. ≥ 70 years) | 0.892 | |||
19 ~ 29 years | 0.520 (0.009–29.191) | |||
30 ~ 39 years | 0.866 (0.013–56.376) | |||
40 ~ 49 years | 1.666 (0.027-101.905) | |||
50 ~ 59 years | 0.486 (0.009–24.964) | |||
60 ~ 69 years | 1.133 (0.018–71.501) | |||
Smoking history | 0.259 (0.052–1.285) | 0.148 | ||
Oral ulcer | 0.173 (0.020–1.532) | 0.115 | ||
Genital ulcer | 0.946 (0.095–9.378) | 0.962 | ||
Ocular lesion | 1.400 (0.148–13.236) | 0.769 | ||
Skin lesion | 2.800 (0.310-25.255) | 0.359 | ||
Arthralgia | 0.818 (0.140–4.764) | 0.823 | ||
Previous treatment for BD | 6.668 (0.785–56.652) | 0.082 | 6.668 (0.785–56.653) | 0.082 |
Previous medical history | 3.498 (0.391–31.289) | 0.263 | ||
Concomitant medical diseases | 3.200 (0.674–15.186) | 0.143 | ||
Concomitant medications | 6.668 (0.785–56.652) | 0.082 | ||
Disease duration (months) | 1.005 (0.989–1.021) | 0.524 | ||
Total amount of adalimumab (mg) | 1.001 (1.000-1.003) | 0.130 | ||
Frequency of adalimumab administration (times) | 1.060 (0.984–1.142) | 0.127 | ||